Tempest Therapeutics reports Q1 2026 net loss of $27.7M, highlights 100% CR rate in TPST-2003 trials

Tempest Therapeutics, Inc.

Ended Q1 with $1.8M cash vs $7.7M at year-end 2025; net loss $27.7M ($2.53/share) vs $10.9M ($3.16) year ago.
TPST-2003 showed 100% complete response in 15 CAR-T-naïve evaluable patients across two trials; no Grade ≥3 CRS/ICANS.
Selected Cincinnati Children's AGCTC as lead manufacturing partner; lentiviral vector received for TPST-2003.
Appointed Andrew Fang, Ph.D., as Head of Business Development to lead partnerships and licensing.
Completed asset acquisition of dual-targeting CAR-T assets from Factor Bioscience and Erigen; $6M private placement closed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tempest Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $27.7 million, EPS $2.53.

Period: the quarter ended March 31, 2026
Net income: $27.7 million
EPS: $2.53
Result: reported results

Exact text from the filing

Net loss and net loss per share for the quarter were $27.7 million and $2.53, respectively, compared to $10.9 million and $3.16, respectively, for the three months ended March 31, 2025.

View on SEC.gov

49 earnings releases filed in the last 30 days. Browse all earnings releases →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-224156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.